Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Becton Dickinson and Co    BDX

Delayed Quote. Delayed  - 09/28 10:02:27 pm
179.17 USD   +0.11%
09/24 BECTON DICKINSO : Dickinson (BDX) Launch Wireless Diagnostic Device
09/23 BECTON DICKINSO : BD Unveils Point-of-Care Diagnostic Device
09/22 BECTON DICKINSO : BD Invests $100 Million In Nebraska Plant To Expan..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Becton Dickinson's 1st-Quarter Earnings Surge; Raises Year-View

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/05/2013 | 12:50pm CEST
   By Saabira Chaudhuri 
 

Becton Dickinson & Co.'s (>> Becton, Dickinson and Co.) fiscal first-quarter earnings more than doubled as the medical device maker recorded revenue growth across all its segments, while margins also widened.

For the current year, Becton raised the bottom end of its revenue guidance, now expecting foreign currency neutral revenue growth starting at 4% versus its prior view starting at 3.5%. It now expects per-share earnings from continuing operations between $5.69 and $5.72, up from its prior view of earnings between $5.58 and $5.64.

The maker of products like surgical blades and test kits last spring struck a deal to sell the bulk of its lab-products business to Corning Inc. (>> Corning Incorporated) for $730 million in cash. Analysts who follow the company noted the sale stripped Becton Dickinson of a cash cow yet also gave it the freedom to focus on businesses with higher growth potential.

Ahead of the company's earnings announcement, analysts at Mizuho Securities downgraded Becton's ratings, noting that the company's life science research business--which makes up about 15% of sales--has been a drag on results for the past year, adding that they see no significant catalysts for the business in the near-term, as the academic market continues to be sluggish.

Still, Chief Executive Vincent A. Forlenza on Tuesday said the company is "starting to see notable results," adding that Becton is "growing revenues across our three segments, driving margin expansion and delivering a higher quality of earnings."

For the quarter ended Dec. 31, Becton Dickinson reported a profit of $625.4 million, or $3.13 a share, compared with $263 million, or $1.21 a share, a year earlier. Per-share earnings from continuing operations were $1.35 versus $1.14.

Revenue increased 3.7% to $1.9 billion. Analysts polled by Thomson Reuters most recently forecast earnings of $1.24 a share on revenue of $1.86 billion.

Gross margin widened to 52.9% from 50.8%.

Becton Dickinson's sales grew 3% in the U.S. and 4.3% internationally. The company's medical unit, its largest by revenue, reported sales rose 3.5%. The diagnostics business posted revenue growth 5%, while bioscience revenue was up 1.7%.

Shares closed Monday at $85.16 and were inactive premarket. The stock has risen 11% in the past three months.

Write to Saabira Chaudhuri at saabira.chaudhuri@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Becton, Dickinson and Co., Corning Incorporated
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BECTON DICKINSON AND CO
09/24 BECTON DICKINSON AND : Dickinson (BDX) Launch Wireless Diagnostic Device
09/23 BECTON DICKINSON AND : BD Unveils Point-of-Care Diagnostic Device
09/22 BECTON DICKINSON AND : BD Invests $100 Million In Nebraska Plant To Expand Insul..
09/22 BECTON DICKINSON AND : BD Unveils Next Generation Wireless Point-of-Care Diagnos..
09/21 BECTON DICKINSON AND : BD Unveils Next Generation Wireless Point-of-Care Diagnos..
09/19 BECTON DICKINSON AND : BD and Vancive Medical Technologies Launch New Vascular D..
09/19 BECTON DICKINSON AND : BD Submits Pre-Market Approval Application to FDA for BD ..
09/19 BECTON DICKINSON AND : BD Expands Portfolio of Reproductive and Sexually Transmi..
09/19 BECTON DICKINSON AND : BD and Vancive Medical Technologies Launch New Vascular D..
09/17 BECTON DICKINSON AND : BD Submits Pre-Market Approval Application to FDA for BD ..
More news
Sector news : Medical Supplies
09/28DJMEDTRONIC : FDA Approves Medtronic's New Automated Insulin Pump
09/28DJMEDTRONIC : FDA Approves Medtronic's New Automated Insulin Pump
09/28DJMEDTRONIC : FDA Approves Medtronic's New Automated Insulin Pump
09/17DJJ&J to Buy Abbott Eye Business -- WSJ
09/16DJJ&J to Buy Abbott's Eye-Surgery Unit for $4.325 billion -- 2nd Update
More sector news : Medical Supplies
News from SeekingAlpha
09/27 My 85 Stock Portfolio Evaluation Of Want To Buy Prices And Yields For Purchas..
09/26 BEST NEAR-TERM PRICE GAINS AHEAD FOR : Medical Supply Stocks
09/20 A Unique Method To Value Dividend Stocks Based On Expected Growth
09/16 FINDING THE GROWTH IN DGI : Dividend Champions
09/15 BECTON, DICKINSON : Big Earnings Increases Should Bring Big Capital Allocation I..
Advertisement
Financials ($)
Sales 2016 12 493 M
EBIT 2016 2 585 M
Net income 2016 1 343 M
Debt 2016 10 201 M
Yield 2016 1,47%
P/E ratio 2016 29,01
P/E ratio 2017 22,08
EV / Sales 2016 3,87x
EV / Sales 2017 3,80x
Capitalization 38 107 M
More Financials
Chart BECTON DICKINSON AND CO
Duration : Period :
Becton Dickinson and Co Technical Analysis Chart | BDX | US0758871091 | 4-Traders
Full-screen chart
Technical analysis trends BECTON DICKINSON ...
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 183 $
Spread / Average Target 2,3%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Vincent A. Forlenza Chairman, President & Chief Executive Officer
Christopher R. Reidy EVP, Chief Financial & Administrative Officer
Ellen R. Strahlman Chief Medical Officer, EVP-Research & Development
Bertram L. Scott Independent Director
Gary A. Mecklenburg Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BECTON DICKINSON AND C..16.15%37 690
TELEFLEX INCORPORATED28.01%7 365
SHANDONG WEIGAO GROUP ..-3.21%3 038
HARTALEGA HOLDINGS BER..--.--%1 836
TOP GLOVE CORPORATION ..--.--%1 471
HOGY MEDICAL CO., LTD.17.27%1 160
More Results